HSBC Holdings
FENC icon

HSBC Holdings’s Fennec Pharmaceuticals FENC Stock Holding History

HSBC Holdings’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10,183
Closed -$60K – 3070
2020
Q3 		$60K Buy
+10,183
New +$71.8K ﹤0.01% 2669

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

HSBC Holdings's FENC Position: Q4 2020 in Review

HSBC Holdings sold out of Fennec Pharmaceuticals (FENC) in Q4 2020, closing a stake of 10,183 shares — an estimated $60K sold.

HSBC Holdings first reported a position in FENC in Q3 2020 and held it in 1 quarter. The position peaked at $60K in Q3 2020. 52 funds tracked by Wall St. Rank hold FENC as of Q4 2020.

  • HSBC Holdings reported no remaining Fennec Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • HSBC Holdings sold 10,183 Fennec Pharmaceuticals shares in Q4 2020, an estimated $60K.
  • HSBC Holdings first reported a position in Fennec Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • HSBC Holdings's Fennec Pharmaceuticals position peaked at $60K in Q3 2020.
  • 52 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q4 2020.

Based on HSBC Holdings's 13F filing for Q4 2020, filed 12 Feb 2021.